| lncRNA name in article | Virus & Strain Name | Dosage & Time point | Cell line | Experiment Type | Fold change | Expression | P-value | Differential expression quantification method | Statistical method | Year | PubMed ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCRNA00219 | Enterovirus 71 (GDFS-3 strain of EV 71) | 10^2 TCID50/mL ;
24 hr |
RD Human embryonal rhabdomyosarcoma cells | Microarray | 2.2277792 | Upregulation | p < 0.05 | GeneSpring GX v12.0 software package (Agilent Technologies) | Not provided | 2013 | 23220233 |
| EPB41L4A-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells | RNA-Seq | 3.551552963 | Upregulation | 1.35E-50 | student's t test | 2020 | 32416070 | |
| EPB41L4A-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 0.2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 1.930025622 | Upregulation | 1.01E-13 | student's t test | 2020 | 32416070 | |
| EPB41L4A-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
A-549 Human adenocarcinomic alveolar basal epithelial cells (ACE2+) | RNA-Seq | 3.287337758 | Upregulation | 0.00033949 | student's t test | 2020 | 32416070 | |
| EPB41L4A-AS1 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Calu-3 Human adenocarcinomic lung epithelialcells | RNA-Seq | 2.252785573 | Upregulation | 3.95E-24 | student's t test | 2020 | 32416070 | |
| ENSG00000224032 | Severe acute respiratory syndrome coronavirus 2 (USA-WA1_2020 strain of SARS-CoV-2) | MOI = 2 ;
24 hr |
Primary Human Bronchial epithelial (NHBE) cells | RNA-Seq | 0.412405048 | Downregulation | 5.90E-05 | two-tailed t-test | 2020 | 32646047 |
* MOI :Multiplicity of infection , TCID :Tissue Culture Infectious Dose